• TechCrunch
• CrunchBase
• More
  • TechCrunch UK
  • TechCrunch France
  • TechCrunch Japan

Rib-X Pharmaceuticals

edit

Rib-X Pharmaceuticals, Inc. is a product-driven small molecule drug discovery and development company focused on the structure based design of new classes of antibiotics.

Milestones

edit

• 
  Rib-X Pharmaceuticals received $3M in Unattributed funding. (2/7/12)
  Posted 2/7/12 at 9:04pm via masshightech.com
• 
  Rib-X Pharmaceuticals received $20M in Unattributed funding. (1/11/11)
  Posted 1/29/11 at 12:58am via rib-x.com
• 
  Rib-X Pharmaceuticals received $25M in Unattributed funding. (1/25/09)
  Posted 4/17/09 at 8:17am via rib-x.com
• 
  Rib-X Pharmaceuticals — has begun a Phase 2b clinical trial of its treatments for acute bacterial skin and skin structure infections (2/8/11)
  Posted 2/9/11 at 3:38am via masshightech.com
• 
  Rib-X Pharmaceuticals — has taken in a $20 million financing, led by Warburg Pincus LLC (1/11/11)
  Posted 1/11/11 at 8:25am via masshightech.com

Videos

Screenshots

edit

Above: Home Page
Uploaded: 5/9/09

Sources

1. Rib-X Pharmaceuticals Announces Positive Phase 2 Study Results for Delafloxacin and a $25 Million Financing (rib-x.com) [edit]
2. Rib-X Pharmaceuticals Raises $20 Million to Advance its Industry-Leading Antibiotics Pipeline (rib-x.com) [edit]
3. Rib-X lands $3M milestone pay from Sanofi deal (masshightech.com) [edit]
4. Rib-X raises $20M to develop antibiotics (masshightech.com) [edit]
5. Rib-X moves skin infection treatment to Phase 2b trial (masshightech.com) [edit]